115 related articles for article (PubMed ID: 22754790)
1. Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer.
Ijichi H
Oncoimmunology; 2012 Jul; 1(4):569-571. PubMed ID: 22754790
[TBL] [Abstract][Full Text] [Related]
2. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.
Sano M; Ijichi H; Takahashi R; Miyabayashi K; Fujiwara H; Yamada T; Kato H; Nakatsuka T; Tanaka Y; Tateishi K; Morishita Y; Moses HL; Isayama H; Koike K
Oncogenesis; 2019 Jan; 8(2):8. PubMed ID: 30659170
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL
J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469
[TBL] [Abstract][Full Text] [Related]
4. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases.
Cheng Y; Ma XL; Wei YQ; Wei XW
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):289-312. PubMed ID: 30703432
[TBL] [Abstract][Full Text] [Related]
5. Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis.
Zhang F; Mulvaney O; Salcedo E; Manna S; Zhu JZ; Wang T; Ahn C; Pop LM; Hannan R
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067390
[TBL] [Abstract][Full Text] [Related]
6. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
7. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Tumor Microenvironment.
Wang K; He H
Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
[TBL] [Abstract][Full Text] [Related]
9. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Awaji M; Saxena S; Wu L; Prajapati DR; Purohit A; Varney ML; Kumar S; Rachagani S; Ly QP; Jain M; Batra SK; Singh RK
FASEB J; 2020 Jul; 34(7):9405-9418. PubMed ID: 32453916
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma.
Kasashima H; Yashiro M; Nakamae H; Masuda G; Kinoshita H; Morisaki T; Fukuoka T; Hasegawa T; Nakane T; Hino M; Hirakawa K; Ohira M
PLoS One; 2017; 12(6):e0178635. PubMed ID: 28575019
[TBL] [Abstract][Full Text] [Related]
11. CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Gαi-2 and Gαq/11.
Chen MC; Baskaran R; Lee NH; Hsu HH; Ho TJ; Tu CC; Lin YM; Viswanadha VP; Kuo WW; Huang CY
J Cell Physiol; 2019 Jul; 234(7):11822-11834. PubMed ID: 30552676
[TBL] [Abstract][Full Text] [Related]
12. Generation of an in vitro 3D PDAC stroma rich spheroid model.
Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
[TBL] [Abstract][Full Text] [Related]
13. Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations.
Ijichi H
World J Clin Oncol; 2011 May; 2(5):195-202. PubMed ID: 21611096
[TBL] [Abstract][Full Text] [Related]
14. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target.
Zhang W; Wang H; Sun M; Deng X; Wu X; Ma Y; Li M; Shuoa SM; You Q; Miao L
Cancer Commun (Lond); 2020 Mar; 40(2-3):69-80. PubMed ID: 32237072
[TBL] [Abstract][Full Text] [Related]
15. Functions of the CXC ligand family in the pancreatic tumor microenvironment.
Lee NH; Nikfarjam M; He H
Pancreatology; 2018 Oct; 18(7):705-716. PubMed ID: 30078614
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer: Stroma and its current and emerging targeted therapies.
Kota J; Hancock J; Kwon J; Korc M
Cancer Lett; 2017 Apr; 391():38-49. PubMed ID: 28093284
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Stellate Cells: The Key Orchestrator of The Pancreatic Tumor Microenvironment.
Thomas D; Radhakrishnan P
Adv Exp Med Biol; 2020; 1234():57-70. PubMed ID: 32040855
[TBL] [Abstract][Full Text] [Related]
18. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises.
Mei L; Du W; Ma WW
J Gastrointest Oncol; 2016 Jun; 7(3):487-94. PubMed ID: 27284483
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions.
Jiang Z; Zhou C; Cheng L; Yan B; Chen K; Chen X; Zong L; Lei J; Duan W; Xu Q; Li X; Wang Z; Ma Q; Ma J
J Exp Clin Cancer Res; 2018 Mar; 37(1):69. PubMed ID: 29587800
[TBL] [Abstract][Full Text] [Related]
20. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance.
Erkan M; Reiser-Erkan C; Michalski CW; Kong B; Esposito I; Friess H; Kleeff J
Curr Mol Med; 2012 Mar; 12(3):288-303. PubMed ID: 22272725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
